Life Sciences Archive » August, 2013

Life Sciences - August, 2013

289 articles

• Arthrex Infringed Rival's Suture Patents, Calif. Jury Says
• Biolitec Escapes Additional Sanctions In AngioDynamics Row
• Genzyme, Sanofi Take Aim At Generic Cancer Drug
• Calif. County's Drug Disposal Mandate Found Constitutional
• PhRMA Urges Fed. Circ. To Rethink Novo Patent Obviousness
• Fosamax MDL To Wind Down More Swiftly Than Merck Wanted
• J&J Faces Contempt For Contacting Glucose-Strip Sellers
• Infant Incubator Maker Slaps Japanese Co. With ITC Suit
• Smith & Nephew Seeks To Ax Doc's Suit Over Device Training
• Meda Scoops Up Asthma Inhaler Maker For $135M
• Key Issues In Handling Product Recalls
• 5 Tips For In-House Counsel Handling Gov't Inquiries
• Everett Can't Bar Acella From Linking Vitamins In Databases
• Imported Food For Thought: FDA On Foreign Food Safety
• Onyx Targeted In Shareholder Suit Over $10.4B Amgen Deal
• FDA Sounds Alarm Over State Biosimilar Drugs Bills
• HHS Slams Ex-InterMune CEO's Challenge To Program Ban
• Disbarred Fen-Phen Attys Take $42M Hit In Ky. High Court
• Takeda Sues Mylan Over Generic Acid Reflux Drug
• Special Masters Back Atty Fee Bid In $688M Vytorin Deal
• Proxy Firms Recommend $9B Actavis-Warner Chilcott Deal
• Bankrupt K-V To Pay $24M To Settle FCA Suit
• NuVasive Medicare Investigation Spurs Securities Class Action
• FDA Concerns Over Testing Co. Trigger Compounder Recalls
• Horizon Pharma Targets Actavis Over Generic Rayos
• Public Citizen Wants HHS To Stop Trials Over Consent Issue
• 10th Circ. Backs Wyeth, Schwarz Win in Generic Reglan Suit
• MDL Panel Combines Diabetes Drug Cancer Suits
• K-V Pharma Judge Greenlights Reorganization Plan
• Endo Health To Pay $225M For Generics Company
• Cleary Seals $495M Simcere Sale To Founder, Partners
• DePuy Hip Implant Attys Call For FDA Investigation
• CMS Plans Further Crackdown On Test-Strip Billing
• Alcon Dodges FCA Suit Over Eye Drug Marketing
• Kohlberg Picks Up Calif. Nutritional Supplements Co.
• Biolitec Loses Bid To DQ Judge In AngioDynamics Row
• Hepatitis B Patent Ruling 'Infected,' BMS Tells Fed. Circ.
• Covidien's Surgical Seal Patent Win Upheld By Fed. Circ.
• 'Good Lab Practices' Don't Apply To Early Device Work: FDA
• Myriad Says It's Immune From Ambry's Antitrust Claims
• NJ Court Nixes Trade Secrets Row Over Generic Cough Syrup
• FDA Details Ethics Panel Duties In Clinical Trials
• Fresenius Hid 'Serious' Health Risks Of GranuFlo, Suit Says
• Amgen's $10B Onyx Buy Takes Training Wheels Off 251(h)
• IP Firm Shakes Supplement Co.'s $4M Malpractice Suit
• Novartis Can't Rush Appeal In Elidel FCA Suit, Judge Says
• Kirkland, Polsinelli Rep Akorn In $640M Hi-Tech Pharma Buy
• How To Counter Product Counterfeiting
• Mylan Says Cephalon's IP Win Based On Wrong Construction
• Nestle Sues RenaGum Maker Over Kidney Disease Treatment
• Peregrine Beats Shareholder Suit Over Lung Cancer Drug
• FDA Details Shelf-Life Testing For Generic Drugs
• Novo Wants High Court To Clarify Foreign Company Liability
• FDA Scolds Drugmakers For Missing Pediatric Study Deadlines
• Covington Reps AstraZeneca In $500M Amplimmune Buy
• Lost Opportunities: Why Cases Settle At The Wrong Time
• Amgen Bags Onyx For $10.4B After Quick Chase
• How They Won It: Fish Nixes $23M Baxter Win With Re-Exam
• Fed. Circ. Affirms Histogen Win In Skin Care IP Suit
• Medtronic Can't Duck Injury Suit Over Bone Graft Device
• Pfizer Settles Former Exec's FCA Suit In 1st Circ.
• Iovate Supplements Don't Build Muscle As Advertised: Suit
• Depomed Says It Was Cheated Out Of Orphan Drug Exclusivity
• FDA Warns Fresenius After Puerto Rico Plant Inspection
• McCarter Further Expands IP Practice With 2 New Hires
• Novartis Sues Par Over Dementia Patch Generic
• Deals Rumor Mill: Amgen, Panasonic, Direct Edge
• Green Light For More Deceptive Labeling Class Actions
• Rainmaker Q&A: Ballard Spahr's Stephen Kastenberg
• Picture This — FDA Taking Inspection Photos
• Who Gives A Sheet About Graphene?
• Biomet's Preemption Bid Fails In Metal Hip Implant MDL
• Stryker Unit Settles OT Miscalculation Collective Action
• Abbott Can't Wipe Out $2.2M Verdict In Humira Case
• Merck Can't Force Fosamax Plaintiffs To Verify Injuries
• Salix Did Its Part In Developing Napo Drug, Atty Argues
• AbbVie Asks Fed. Circ. To Revive Antibody Patent Suit
• Purdue Sues TWi Over Insomnia Drug Generic Plans
• St. Jude, Volcano Can't Flip Heart Device IP Verdicts
• Jones Day Adds Life Sciences, Tech M&A Partner In Atlanta
• ACLU, Others Blast Myriad Bid To Halt Rival Gene Tests
• Deals Rumor Mill: HP, Sharp, KKR
• Sanofi Settles Inflammation-Drug Kickback Claims
• Bard Settles 2nd Vaginal Mesh Bellwether On Trial's 1st Day
• Patient Groups Decry ACA Medicaid Drug Coverage Rule
• OTC Drug Group Wants Children's Dosage On Med Labels
• A-Rod's Cousin Gets Deposition Delayed In MLB Drug Suit
• Reckitt Sues To Block Par's Generic Suboxone
• 3rd Circ. Takes Ascertainability More Seriously
• Watchdog Urges FDA To Put 'Black Box' Warning On Plavix
• FDA Finds Drug Co. Clinical Tests Lack Diversity
• Mallinckrodt Breached Pain Med Licensing Deal, Nuvo Says
• Expanding Miles & Stockbridge Nabs 7 From Baker Donelson
• Sandoz Wants Rapaflo Infringement Suit Trimmed
• Law Firms' Intervention Bid Nixed In GSK Class Action
• Ackman Says Regulators Eyeing Herbalife, Sticks To $1B Short
• Allergan Demands FDA Retract Generic Restasis Guidance
• Deals Rumor Mill: TPG, Blackstone, AIG
• 6th Circ. Took A Wrong Turn In Omnicare Case
• Trio Of Favorable Preemption Decisions For NJ Pharma Cos.
• Rainmaker Q&A: Sterne Kessler's Robert Sterne
• Dumpster Diving For Deleted Files: When Is It Worth It?
• Eisai's Attacks Pressure Feds To Patch Exclusivity Holes
• Bayer Wants Out Of Probiotic False Ad Class Action
• Texas Panel Quashes $10M Judgments Against Fen-Phen Atty
• FDA Links Foreign Drugs To Life-Threatening Side Effects
• Shire Billed Medicaid For Off-Label ADHD Drug Use, La. Says
• Rainmaker Q&A: Ulmer & Berne's Michael Switzer
• Stryker Says Junk-Fax Class Action Would Hurt Doctors
• Crisis Mismanagement And Other Cautionary Tales
• New FDA Drug Security Program Targets Dubious Imports
• PE Activity Is Increasing In The Urgent Care Space
• FDA Warns Drug Ingredient Maker Over Testing Issues
• How Fed. Circ. May View Post-AIA Invention Sales Offers
• Russian Antitrust Watchdog Warns Teva Over MS Drug
• Okla. Judge Halts State Plan B Restrictions
• Icahn Rips Investor's Bid To Bar Potential Herbalife Deal
• Brookstone Beats 'Generic' Acne Gel False Ad Suit In 11th Circ.
• Merck, Plaintiffs Bicker Over Fosamax MDL Wind-Down Plans
• Eisai Slams DEA Over Delay In Scheduling Seizure Med
• Gibson Dunn, Homburger Aid St. Jude's $170M Endosense Buy
• Orthofix Flooded With Investor Suits Over Restated Earnings
• ITC Launches New Patent Probe Of Sleep Aid Devices
• Becton Can't Dodge Rival Syringe Maker's Antitrust Claims
• 3rd Circ. Revives Device Co. Recoupment Suit Against Aetna
• Hospira Can't Shake Ex-USC Player's Pain Med Claims
• Medical Supplier Hits Ch. 11 Planning $22M Sale
• Atty Should Forfeit $5M From NFLer's Stock Scheme, US Says
• K-V Creditors Slam Senior Bondholders' Bid For Interest
• Investor Sues RyMed Directors Over Loan Default
• Teva Sues Perrigo Over ProAir Generic Plans
• Rainmaker Q&A: Fish & Richardson's Juanita Brooks
• Weil Guides Bard In $200M Deal For Hemostat Maker Medafor
• Agave BioSystems Settles FCA Claims Over Contract Staffing
• A Win For Prop 65 Defendants, Lessons For All
• Windsor Proves Court Erred In Booting Gay Juror, GSK Says
• Shire Wins Dismissal Of Generic Adderall Antitrust Suit
• US Backs Medtronic In High Court Burden-Of-Proof Case
• No Mass Tort For Tylenol Liver Cases In NJ
• Roche Asks NJ High Court To Kick Judge Off Accutane Suits
• FTC Wants To Extend Actavis To Authorized Generics Deals
• Drug Co.'s Readmissions Work Survives Kickback Scrutiny
• Health Plans Sue Abbott Over Depakote Off-Label Scheme
• 7th Circ. Revives Baxter Investor Suit Over $588M Recall
• FDA Awareness Letters Have Impact, Allergan Counsel Says
• Rainmaker Q&A: Sterne Kessler's Eric Steffe
• Sekisui Sanctioned For Email Deletion In Merger Fight
• Cardinal Health Suit Lacked Pre-Suit Demand, 6th Circ. Says
• Labeling Update Claims Survive Dismissal In Fosamax MDL
• Bard Hit With $2M Verdict In Vaginal Mesh Bellwether
• Rivals Fight Myriad Bid For Gene Test Ban In Patent Case
• Merck, Plaintiffs Fail To Reach Deal In Fosamax Jaw MDL
• Antibiotic Type Poses Severe Nerve Damage Risk, FDA Says
• Novo Nordisk Sues Amneal Over Vagifem Generic
• UnitedHealth Slams Law Firms' Intervention Bid In GSK Action
• Univ. Of Wis. Defends Stem Cell Patent At Fed. Circ.
• Deals Rumor Mill: Amgen, Newfield, Verizon
• Homeopathic Drugmaker Puts Up $1M To End False Ad Claims
• Galderma Fights Appeal Fee Bid In NYU Oracea Dispute
• Rainmaker Q&A: Choate Hall's Paul Popeo
• Calif. Gov. Vetoes Bill Allowing Payment For Egg Donations
• Siemens Gets Fresh Shot At HIV Test Patent
• Novartis Opens Probe Into Whistleblower's Kickback Claims
• J&J, DePuy Fail To Split Up Consolidated Hip Implant Trial
• FDA Knew Compounder Had Unsterile Practices: Watchdog
• The Cost, And Ethics, Of Doing (Legal) Business
• FCA's Reach At Stake As DOJ Jumps Into 1st Circ. Fight
• Doc Access Deal OK'd In SAC Insider Trading Class Action
• Avanir Settles With Sandoz Over Nuedexta Generic Plans
• Watson Pays $8.5M To Resolve Medicaid Fraud Claims
• Gray Zone Between FDA And FTC Nutraceutical Regulation
• Investors In Dissolved Biotech Co. Sued Too Late, Judge Rules
• FDA Outlines Safety Testing For Telehealth Medical Devices
• Medical Foods Don't Require A Prescription, FDA Says
• Pharmstandard To Pay $590M For Pharmaceutical Supply Co.
• Gilead, Roche Settle Ranexa Patent Suit Against Lupin
• Kaye Scholer Snags Pepper Hamilton Antitrust Partner
• Acne Drug Licensing Suit Allowed To Stay In Court
• Sheppard Mullin Adds Finance, Patent Pros In Bay Area
• FDA Accused Of Cutting Obesity Drug's Exclusivity Short
• Deals Rumor Mill: Blackstone, Onyx, Steinway
• Rainmaker Q&A: Wolf Greenfield's Edward Gates
• $818M Deal Lowballs Trius On Brink Of Drug Launch, Suit Says
• Fed. Circ. Revives Leo Psoriasis Drug Patent
• Novel Labs Asks Fed Circ. For Reversal In Suprep Suit
• GSK Triumphs In Avodart Patent Challenge
• Merck Wants Fosamax Plaintiffs To Cough Up Evidence
• Mylan Ducks $15M Bristol-Myers Contract Suit Over HIV Drug
• AstraZeneca Defends Pulmicort Patents At Fed. Circ.
• Eyeing Antibiotics, Drugmakers Ask For Longer Pathogen List
• Columbia Labs Slams Investor Suit Over Rejected Drug
• ACA Push For Cost-Effective Care Spurs $200M Medtronic Buy
• Fed. Circ. Won't Review Invalidity Ruling Over Yaz Patent
• Sanofi Faces China Bribery Probe Over Whistleblower Claims
• Compounding Pharmacy Linked To Infections Issues Recall
• Pa.'s Series Of Pharma Cases Give RLD Theory Some Legs
• Vital Shakes False Ad Suit Over Fat Loss Supplement
• Allergan Eye Antibiotic Patent Claims Ruled Invalid
• With Stark Law Loophole Under Fire, Docs Eye Bottom Line
• Depomed Sues Banner, Watson Over Proposed Generic Zipsor
• Ulmer & Berne Nabs Skadden Litigation Pro In Chicago
• FDA Links 15 Infections To Texas Compounding Pharmacy
• Fed. Circ. Backs Sequenom Bid To Bar Ariosa Prenatal Test
• Axis Scores Docs In D&O Coverage Fight With BioChemics
• Judge Knocks Bellwether Pool In Boston Scientific Mesh MDL
• Deals Rumor Mill: BlackBerry, Smithfield, Amgen
• Supplement Maker Can't Shake Glucosamine False Ad Action
• FDA Won't Approve Wright Medical Bone Graft Application
• GlaxoSmithKline Launches $50M Biotech Venture Fund
• India Nixes Patents For Allergan Glaucoma Drugs
• More Wiggle Room In Gluten-Free Labeling
• USPTO Re-Exam Considerations After Fresenius V. Baxter
• Fraud Claims Escape Preemption In Medtronic Bone Graft Suit
• Shire Urges Fed. Circ. To Block Actavis' Generic Lialda
• Supernus Sues Actavis, Watson Over Oxtellar XR Patents
• Judge To Review Cephalon Docs In FTC Pay-For-Delay Row
• Wyeth To Pay $14M In Attys' Fees In Pristiq Class Action
• Pfizer Can't Escape Neurontin Antitrust MDL
• Rainmaker Q&A: Seyfarth's Gerald Maatman
• PSS Says Ex-Workers Took Trade Secrets, Clients To New Co.
• Compounder Wins Transfer Of Eye Injury Suits To La.
• FDA Faces Dueling Demands On Antibiotic Clinical Trials
• Chinese Authorities Probe Danish Drug Cos. Amid GSK Fallout
• Pharmavite Ducks Class Cert. In Vitamin Supplement Suit
• How FDA's Adverse Event Reporting System Impacts Drug Cos.
• DaVita Seeks To Toss Dialysis Products Class Action
• Stryker Wins $210M In Device Patent Suit Against Zimmer
• TPG Looking To Sell Canadian Drugmaker For $3B
• Whistleblowers Rip Boston Scientific's Bid To Bar Evidence
• GNC Supplements Do Not Increase Blood Flow, Suit Says
• SAC Trader Accused Of Obstruction In $276M Investor Suit
• Fed. Circ. Revives Galderma's Patents On Rosacea Drug
• Medical Co. Hit With Investor Suit Over $20M Sham Financing
• FDA Ordered To Turn Over Docs In Truvada FOIA Suit
• Vinson & Elkins Lures Ex-Hogan Lovells Partner To SF Office
• Deals Rumor Mill: Amgen, Wal-Mart, Cinven
• Fed. Circ. Affirms J&J Contact Lens Patent Victory
• Walgreen Can't Duck Supplement False Ad Suit
• AstraZeneca Can't Duck Patent Claim Over Symbicort Inhaler
• Clinical Trial Oversight Must Focus On Major Risks, FDA Says
• JPML Consolidates Effexor Birth Defect Actions In Pa.
• Shareholder Urges Taro To Side With Activist's Board Picks
• Cobalis Suit Over Hedge Fund Scheme Tossed In NJ
• Global Patchwork Of Bribery Laws Complicates GSK Defense
• Vision Pharma Seeks $3M From Sunrise For Adulterated Drugs
• Andrx Can't Beat AstraZeneca's Prilosec Patent Suit
• Hedge Fund Can Seek Digirad Proxy Revote At Trial
• Arnold & Porter Adds FCA, Health Care Fraud Pro
• CMS Revises National Payment Policy For Drugs, Devices
• Novartis Seeks To Stop Hospira From Selling Zometa Generic
• Ambry Hits Myriad With Antitrust Claim In Gene Test IP Row
• Merck Investors Rip Fee Requests In $688M Vytorin Deal
• Ex-InterMune CEO Urges Justices To Review Fraud Conviction
• What May Come Of CMS' Proposed Device Regulations
• GTCR Commits Up To $200M To Specialty Pharma Venture
• Kelley Drye Lures Pharma IP Pro From Edwards Wildman
• Warner Chilcott, Mylan Deal OK'd In Birth Control IP Row
• $200M Cardinal, Owens & Minor Antitrust Suit Trimmed
• 6th Circ. OKs Forfeiture Order In Fen-Phen Attys Suit
• McDermott Ducks Health IT Client's IP Theft Suit
• Warner Chilcott Says FCA Kickback Suit Is Too Vague
• Pfizer Targets Wockhardt In Generic Toviaz Suit
• Ex-SAC Trader Says Criminal Docs Off-Limits In Class Suit
• In Myriad, Did Supreme Court Confuse Its Own Precedent?
• Stay Tuned For More Developments In GINA
• Enzo, ABI Lose New Trial Bids After $49M DNA Patent Verdict
• Takeda Ruling Could Limit FCA Enforcement, 1st Circ. Hears
• Preemption May Yet Doom State-Law Reglan Claims
• Actelion Forks Over $250M For Pa. Drugmaker
• High Court's Sorrell Ruling Yet To Transform Drug Marketing
• FDA Unveils User Fee Hikes To Fund Review Of Drugs, Devices
• India Revokes GSK Breast Cancer Drug Patent
• Baxter Asks Fed. Circ. To Rethink Nixing $23M Patent Award
• House Votes To Give Congress Power Over Costly Regulations
• The Reappearance Of Ticking Fees In Delayed Closings
• Kilpatrick Townsend Grows In Atlanta With Arnall Golden Pros
• What HRSA's New Rule Means For Hospitals And Pharma Cos.
• Drugmaker UCB Sues Rival Sun Over Planned Vimpat Generic
• Becton Dickinson Pays $22M To Settle Syringe Antitrust Suits
• J&J Fined In Landmark Chinese Antitrust Loss
• Walgreen Shareholders Sue Over $80M DEA Payout
• Nova Yanks 62M Diabetes Test Strips Over False Readings
• FDA Links Acetaminophen To Fatal Skin Disease
• Med School Slaps AstraZeneca With Crestor Patent Suit
• 8th Circ. Says Petco Heater Not Covered In Medtronic Fire Suit
• Genzyme Lied About Plant Contamination, 1st Circ. Told
• Sen. Slams Walgreen After Employee Trumpets 340B Profits
• Putting Daubert In Proper Perspective
• Rainmaker Q&A: Crowe & Dunlevy's Karen Rieger